The mission of the Arizona Cancer Center (AZCC) is to prevent and cure cancer. To continue that mission, this application requests a 5-year renewal of the Cancer Center Support Grant (CCSG). The AZCC was founded as a Division of the College of Medicine (COM), University of Arizona (UA) in 1976. It obtained a CCSG in 1978 and was designated a Comprehensive Cancer Center by the NCI in 1990. To accomplish our mission, the basic and translational/clinical and cancer prevention and control research is carried out in six programs, including molecular genetics, cancer metastases and signaling, cancer imaging and technology, gastrointestinal cancer, therapeutic development and cancer prevention and control. These programs are supported by 20 shared services, which help the AZCC (the whole) be greater than the sum of the parts. Since the last renewal, the AZCC team has substantially increased their peer reviewed funding and garnered additional program projects and a GI cancer SPORE. Those accomplishments demonstrate the interdisciplinary activities of the Cancer Center. As we hope the reviewers will see, the team has made considerable progress in their basic and clinical science, including bringing two therapeutic and five prevention agents forward into clinical trials. The renewal outlined in this application is critical to keep us working to accomplish our mission.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023074-29S3
Application #
7282584
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1978-09-01
Project End
2008-06-30
Budget Start
2006-09-27
Budget End
2007-06-30
Support Year
29
Fiscal Year
2006
Total Cost
$340,636
Indirect Cost
Name
University of Arizona
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26
Padilla-Rodriguez, Marco; Parker, Sara S; Adams, Deanna G et al. (2018) The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun 9:2980
Hupple, Clinton W; Morscher, Stefan; Burton, Neal C et al. (2018) A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206
Smithey, Megan J; Venturi, Vanessa; Davenport, Miles P et al. (2018) Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proc Natl Acad Sci U S A 115:E6817-E6825
Maisel, Sabrina; Broka, Derrick; Schroeder, Joyce (2018) Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget 9:6463-6477
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Augustus, Gaius J; Ellis, Nathan A (2018) Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. Am J Pathol 188:291-303

Showing the most recent 10 out of 1336 publications